Global healthcare company Eli Lilly and Company completed the technology transfer of multi-drug resistant tuberculosis (MDR-TB) drug Cycloserine in India to Shasun Chemicals and Drugs Ltd. Chennai, the company said here.
"After close consultation with global TB experts, Lilly embarked on a novel approach: transferring its manufacturing technology and know-how for capreomycin and cycloserine free of charge to seven manufacturers.
"In India, the technology transfer of second line drug cycloserine has been completed with Shasun Chemicals and Drugs Ltd. Chennai," the company said in a statement.
Eli Lilly said all seven partners have received regulatory approvals, including those from the World Health Organisation's pre-qualification programme and other stringent regulatory authorities, to supply high quality versions of these two medicines to people with MDR-TB.
